文献速递流行病学与生物统计真实世界研究与卫生经济

胰岛素和/或口服降糖药治疗的妊娠糖尿病女性一年及以后代谢随访核心结局集研究方案

Metabolic follow-up at one year and beyond of women with gestational diabetes treated with insulin and/or oral hypoglycaemic agents: study protocol for the identification of a core outcomes set using a Delphi survey.
PubMed 文献 · Trials · 2019-01-05

该研究方案旨在为曾患妊娠糖尿病(GDM)且接受胰岛素和/或口服降糖药治疗的女性,制定一年及以后代谢随访的核心结局集(COS)。方案包括三部分:系统综述既往随机对照试验报告的结局、三轮在线德尔菲调查对结局进行优先排序、共识会议确定最终COS。该方案是统一GDM女性随访结局选择和报告的第一步。

要点

  • GDM女性远期代谢并发症风险高,但长期随访和结局报告缺乏标准化。
  • 核心结局集(COS)将通过系统综述、德尔菲调查和共识会议制定。
  • 目标人群为接受胰岛素和/或口服降糖药治疗的GDM女性,随访至少1年。

核心结论

  • 该方案旨在制定GDM女性代谢随访的核心结局集,以统一结局选择和报告,减少报告偏倚并促进研究间比较。

研究设计与样本

  • 研究方案包括三部分:系统综述、三轮在线德尔菲调查和共识会议。
  • 目标人群为曾患GDM且接受胰岛素和/或口服降糖药治疗的女性,随访时间点为1年及以后。

临床怎么用

  • 该COS制定后可用于规范GDM女性长期代谢随访的结局选择和报告。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Gestational diabetes (GDM) is associated with an increased lifetime risk for the development of glucose abnormalities, metabolic syndrome, cardiovascular disease, depression and tumours. Despite this high risk of additional comorbidities, there is no standardised approach to the long-term follow-up of women with a previous diagnosis of GDM. Also, there is no standardisation of outcome selection and reporting in studies involving this population. This increases the risk of reporting bias and reduces the possibility of meaningful comparisons between studies. The aim of this study is to develop a protocol for a core outcome set (COS) for the metabolic follow-up at 1 year and beyond of women with previous GDM treated with insulin and/or oral hypoglycaemic agents. METHODS/DESIGN: This protocol will describe the steps that will be taken in order to develop the COS. The study will consist of three parts: (1) A systematic review of the literature of the outcomes reported in previous randomised controlled trials of the follow-up at 1 year and beyond of women with GDM treated with insulin and/or oral hypoglycaemic agents; (2) A three-round, online Delphi survey with key stakeholders in order to prioritise these outcomes; and (3) A consensus meeting where the final COS will be decided. DISCUSSION: The proposed protocol is the first step in developing a COS that will bring consistency and uniformity to outcome selection and reporting in GDM women treated with insulin and/or oral hypoglycaemic agents.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Bogdanet D, Egan A, Fhelelboom N, et al. Metabolic follow-up at one year and beyond of women with gestational diabetes treated with insulin and/or oral hypoglycaemic agents: study protocol for the identification of a core outcomes set using a Delphi survey. Trials. 2019. PMID: 30611300. doi:10.1186/s13063-018-3059-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。